Head-to-head evidence
Salbutamol HFA-152a vs Salmeterol (DISKUS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 477 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events, but results are not posted, so whether the primary comparison was favorable cannot be determined.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
Salmeterol (DISKUS)
Marketed by GlaxoSmithKline
NCT00395304 · Phase 3 · completed
This was a rigorously designed, fully blinded, randomized crossover trial with a clinically meaningful composite primary measure, but the results available here do not show how the fluticasone-plus-salmeterol arm specifically compared with the other step-up therapies, so the salmeterol-specific effect cannot be confirmed from this data.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Salbutamol HFA-152a's landscape · Salmeterol (DISKUS)'s landscape